


**REMARKS**

In response to the restriction requirement, Applicants provisionally elect with traverse the invention set forth in Group II, drawn to compounds, compositions, and method of use of the compounds of formula I where A-B is  $\text{NR}^5\text{-SO}_2$  and p is 2.

Regarding the election of species, please tentatively elect the compound of example 19:

*N*-[(1*S*,2*R*)-3-(Cyclopropylamino)-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-1-methyl-3,4-dihydro-1*H*-[1,2,5]thiadiazepino[3,4,5-*h*]indole-9-carboxamide 2,2-dioxide



This compound is encompassed by claims 9-17 and 19-21.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,



Bonnie L. Deppenbrock

Attorney for Applicant

Registration No. 28,209

Date: 25 July 2008

GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive

P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone: 919-483-1577

Facsimile: 919-483-7988